Multiplex colon cancer marker panel

Abstract

The present invention provides a specific combination of colon cancer markers based on statistical knowledge, which is capable of detecting a larger number of colon cancer patients in an earlier stage while maintaining high specificity. A multiplex colon cancer marker panel comprising a combination of five colon cancer markers of Carcinoembryonic antigen-related cell adhesion molecule 5, Carbohydrate antigen 19-9, Galectin-4, APEX nuclease and Actin-related protein 2. A method for analyzing colon cancer markers using multiplex colon cancer marker panel.

What is claimed is: 
     
         1 . A multiplex colon cancer marker panel comprising a combination of five colon cancer markers of Carcinoembryonic antigen-related cell adhesion molecule 5, Carbohydrate antigen 19-9, Galectin-4, APEX nuclease and Actin-related protein 2. 
     
     
         2 . A multiplex colon cancer marker panel comprising a combination of four colon cancer markers arbitrarily selected from five colon cancer markers of Carcinoembryonic antigen-related cell adhesion molecule 5, Carbohydrate antigen 19-9, Galectin-4, APEX nuclease and Actin-related protein 2. 
     
     
         3 . A multiplex colon cancer marker panel comprising a combination of three colon cancer markers of:
 Carcinoembryonic antigen-related cell adhesion molecule 5, Carbohydrate antigen 19-9, and APEX nuclease;   Carcinoembryonic antigen-related cell adhesion molecule 5, Carbohydrate antigen 19-9, and Actin-related protein 2;   Carcinoembryonic antigen-related cell adhesion molecule 5, Galectin-4, and APEX nuclease;   Carbohydrate antigen 19-9, Galectin-4, and APEX nuclease;   Carbohydrate antigen 19-9, Galectin-4, and Actin-related protein 2; or   Carbohydrate antigen 19-9, APEX nuclease, and Actin-related protein 2.   
     
     
         4 . A multiplex colon cancer marker panel comprising a combination of two colon cancer markers of Carbohydrate antigen 19-9 and APEX nuclease. 
     
     
         5 . A method for analyzing colon cancer markers, the method comprising the steps of:
 acquiring respective measured values of five colon cancer markers of Carcinoembryonic antigen-related cell adhesion molecule 5, Carbohydrate antigen 19-9, Galectin-4, APEX nuclease, and Actin-related protein 2 in a biological sample derived from an individual;   normalizing the respective measured values of the five colon cancer markers to derive respective probability scores of the five colon cancer markers and deriving an average of the probability scores; and   evaluating the average of the probability scores based on whether the average is higher or lower than a criterion value for the five colon cancer markers.   
     
     
         6 . A method for analyzing colon cancer markers, the method comprising the steps of:
 acquiring respective measured values of four colon cancer markers arbitrarily selected from five colon cancer markers of Carcinoembryonic antigen-related cell adhesion molecule 5, Carbohydrate antigen 19-9, Galectin-4, APEX nuclease, and Actin-related protein 2 in a biological sample derived from an individual;   normalizing the respective measured values of the four colon cancer markers to derive respective probability scores of the four colon cancer markers and deriving an average of the probability scores; and   evaluating the average of the probability scores based on whether the average is higher or lower than a criterion value for the four colon cancer markers.   
     
     
         7 . A method for analyzing colon cancer markers, the method comprising the steps of:
 acquiring respective measured values of three colon cancer markers of:   Carcinoembryonic antigen-related cell adhesion molecule 5, Carbohydrate antigen 19-9, and APEX nuclease;   Carcinoembryonic antigen-related cell adhesion molecule 5, Carbohydrate antigen 19-9, and Actin-related protein 2;   Carcinoembryonic antigen-related cell adhesion molecule 5, Galectin-4, and APEX nuclease;   Carbohydrate antigen 19-9, Galectin-4, and APEX nuclease;   Carbohydrate antigen 19-9, Galectin-4, and Actin-related protein 2; or   Carbohydrate antigen 19-9, APEX nuclease, and Actin-related protein 2 in a biological sample derived from an individual;   normalizing the respective measured values of the three colon cancer markers to derive respective probability scores of the three colon cancer markers and deriving an average of the probability scores; and   evaluating the average of the probability scores based on whether the average is higher or lower than a criterion value for the three colon cancer markers.   
     
     
         8 . A method for analyzing colon cancer markers, the method comprising the steps of:
 acquiring respective measured values of two colon cancer markers of Carbohydrate antigen 19-9 and APEX nuclease in a biological sample derived from an individual;   normalizing the respective measured values of the two colon cancer markers to derive respective probability scores of the two colon cancer markers and deriving an average of the probability scores; and   evaluating the average of the probability scores based on whether the average is higher or lower than a criterion value for the two colon cancer markers.